Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

Oscar Murphy has an aggressive form of the blood cancer and is the first to get CAR-T therapy in the UK.

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

CAR T-cell therapy modifies a patient's immune cells to target cancer, offering potential cures for blood cancers like lymphoma and myeloma. Up to 40% of lymphoma patients may achieve remission after ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...